AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18566793 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder sparing approaches (specific interventions not detailed).
Number of subjects: 0
Study 18566793 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative or less invasive treatment approaches (specific interventions not detailed).
Number of subjects: 0
Study 16501948 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally applied nasal decongestant agents: 2 drops twice/day of xylometazoline nasal solution 0.1% and 100microg budesonide (NDCA group, n=39)
Number of subjects: 79
Study 12502488 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous hyperinsulinemia
Number of subjects: 9
Study 12502488 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 9
Study 12502488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15241837 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 50
Study 15241837 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 50
Study 10198296 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 5, 12 units daily for 5 days
Number of subjects: 28
Study 10198296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 10198296 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 1, 12 units for 1 day
Number of subjects: 28
Study 10198296 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 28
Study 7775175 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2 atmospheres of pressure (hyperbaric)
Number of subjects: 20
Study 7775175 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen at 1 atmosphere of pressure (normobaric)
Number of subjects: 20
Study 2110271 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 mg rt-PA
Number of subjects: 186
Study 2110271 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4 mg rt-PA
Number of subjects: 186
Study 2110271 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.8 mg rt-PA
Number of subjects: 186
Study 2110271 — intervention group
Group type: EXPERIMENTAL
Intervention: 25.6 mg rt-PA
Number of subjects: 186
Study 2110271 — intervention group
Group type: EXPERIMENTAL
Intervention: 33.3 mg rt-PA
Number of subjects: 186
Study 2110271 — intervention group
Group type: EXPERIMENTAL
Intervention: 50.0 mg rt-PA
Number of subjects: 186
Study 552293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (oral administration)
Number of subjects: 12
Study 552293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (intravenous administration)
Number of subjects: 12
Study 30668211 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb taping for 4 weeks (Group A)
Number of subjects: 20
Study 30668211 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb taping for 2 weeks (Group B)
Number of subjects: 20
Study 28179230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose computed tomography (CT) screening
Number of subjects: 5203
Study 25791144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy (CBT) sessions (n = 45)
Number of subjects: 119
Study 25791144 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (n = 44)
Number of subjects: 119
Study 23714335 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 1896
Study 23714335 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 1896
Study 21233606 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids group (n = 105) - received 500 mg hydrocortisone immediately before hepatic‐pedicle clamping, followed by 300 mg on POD 1, 200 mg on POD 2, and 100 mg on POD 3
Number of subjects: 210
Study 21233606 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 105)
Number of subjects: 210
Study 21233606 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids group
Number of subjects: 210
Study 21233606 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 210
Study 20064183 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal, pulsed, 1064‐nm Nd:YAG laser treatment
Number of subjects: 20
Study 20064183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1064‐nm Nd:YAG laser and removal of cell debris by suction cannula
Number of subjects: 20
Study 17317751 — intervention group
Group type: EXPERIMENTAL
Intervention: SupEX (supine cycling at 60 r.p.m.)
Number of subjects: 8
Study 17317751 — intervention group
Group type: EXPERIMENTAL
Intervention: 80EX (upright cycling at 80 r.p.m.)
Number of subjects: 8
Study 17317751 — intervention group
Group type: COMPARATOR
Intervention: Control (upright cycling at 60 r.p.m.)
Number of subjects: 8
Study 15088864 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 0
Study 15088864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11259985 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysin (400 mg oral dose)
Number of subjects: 7
Study 9498885 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Administration (PCEA)
Number of subjects: 30
Study 9498885 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural Infusion
Number of subjects: 30
Study 9498885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study 7893585 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg BTS 67 582
Number of subjects: 16
Study 7893585 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg BTS 67 582
Number of subjects: 16
Study 7893585 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg BTS 67 582
Number of subjects: 16
Study 7893585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2822795 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (0.5 mg i.m; every 12 h)
Number of subjects: 6
Study 2822795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (50 mg orally, every 6 h)
Number of subjects: 6
Study 31809408 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Tramadol
Number of subjects: 16
Study 31809408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31099799 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD education intervention and nurse teaching
Number of subjects: 54
Study 31099799 — intervention group
Group type: COMPARATOR
Intervention: Nurse teaching
Number of subjects: 54
Study 29028776 — intervention group
Group type: EXPERIMENTAL
Intervention: Western classical music
Number of subjects: 96
Study 29028776 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish classical music
Number of subjects: 96
Study 29028776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 25589191 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 709
Study 25589191 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed-cisplatin (LUX-Lung 3)
Number of subjects: 709
Study 25589191 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin (LUX-Lung 6)
Number of subjects: 709
Study 25589191 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib for del19-positive tumours
Number of subjects: 709
Study 25589191 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy for del19-positive tumours
Number of subjects: 709
Study 25589191 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib for Leu858Arg-positive tumours
Number of subjects: 709
Study 25589191 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy for Leu858Arg-positive tumours
Number of subjects: 709
Study 22843347 — intervention group
Group type: EXPERIMENTAL
Intervention: LHA intervention with behavioral counseling and nicotine patches
Number of subjects: 147
Study 20930640 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral Suppression (VS) group
Number of subjects: 254
Study 20930640 — intervention group
Group type: COMPARATOR
Intervention: Drug Conservation (DC) group
Number of subjects: 254
Study 19299775 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon block (SB) with 0.06-0.08 mL/kg of 2% lidocaine and 0.5% bupivacaine (50:50) mixture and simultaneous 0.2 mL/kg normal saline IV
Number of subjects: 114
Study 19299775 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon block (SB)
Number of subjects: 114
Study 19299775 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (IV F) 1 microg/kg (0.2 mL/kg of 5 microg/kg)
Number of subjects: 114
Study 19299775 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (IV F)
Number of subjects: 114
Study 17582921 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus vaccine (3-dose schedule: 0, 2, and 6 months)
Number of subjects: 18000
Study 17582921 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus vaccine
Number of subjects: 18000
Study 17582921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study 15213043 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 or 100 microg Se (as sodium selenite)
Number of subjects: 22
Study 15213043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12866806 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol treatment
Number of subjects: 22
Study 9797204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 200 mg q12h with indinavir 800 mg q8h
Number of subjects: 5
Study 9797204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg q12h with indinavir 600 mg q8h
Number of subjects: 5
Study 9797204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg q12h with indinavir 400 mg q8h
Number of subjects: 5
Study 9797204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg q12h with indinavir 400 mg q8h
Number of subjects: 5
Study 9797204 — intervention group
Group type: COMPARATOR
Intervention: Indinavir 800 mg q8h (standard regimen)
Number of subjects: 5
Study 8591964 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment schemes including individualized therapy based on risk factors.
Number of subjects: 0
Study 8591964 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline treatment for stage III and IV favorable histology Wilms tumor.
Number of subjects: 0
Study 2528405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (0.25 to 12 micrograms.min‐1)
Number of subjects: 6
Study 2528405 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 2528405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 6
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray therapy (XRT)
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU + XRT
Number of subjects: 225
Study 349395 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no further treatment)
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (young)
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of seizures
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial nerve symptoms
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated tumor
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal tumor location
Number of subjects: 225
Study 349395 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy (operation biopsy only)
Number of subjects: 225
Study 31980638 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting nifedipine
Number of subjects: 0
Study 31980638 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release nifedipine
Number of subjects: 0
Study 31980638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31152598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Release Tacrolimus
Number of subjects: 18
Study 31152598 — intervention group
Group type: COMPARATOR
Intervention: Immediate Release Tacrolimus
Number of subjects: 18
Study 28939406 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Losartan Potassium/Chlorthalidone (A/L/C)
Number of subjects: 330
Study 28939406 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/Losartan Potassium (A/L)
Number of subjects: 330
Study 26154787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 5 mg
Number of subjects: 293
Study 26154787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 15 mg
Number of subjects: 293
Study 26154787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 50 mg
Number of subjects: 293
Study 26154787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 293
Study 26154787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg
Number of subjects: 293
Study 26154787 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 293
Study 26154787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 26154787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (all doses)
Number of subjects: 293
Study 26154787 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections
Number of subjects: 293
Study 23471226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 42
Study 23471226 — intervention group
Group type: COMPARATOR
Intervention: Full-length silicone insole
Number of subjects: 42
Study 21194255 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived CD133(+) cells
Number of subjects: 6
Study 21194255 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow-derived mononuclear cells
Number of subjects: 6
Study 19103946 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral reasoning exercise
Number of subjects: 2020
Study 19103946 — intervention group
Group type: COMPARATOR
Intervention: No moral reasoning exercise (control group)
Number of subjects: 2020
Study 16504646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 1 mg
Number of subjects: 63
Study 16504646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 3 mg
Number of subjects: 63
Study 16504646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 10 mg
Number of subjects: 63
Study 16504646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 30 mg
Number of subjects: 63
Study 16504646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 90 mg
Number of subjects: 63
Study 16504646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16504646 — intervention group
Group type: COMPARATOR
Intervention: Marijuana smoking (2.64% THC) after placebo rimonabant
Number of subjects: 63
Study 16504646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (any dose)
Number of subjects: 63
Study 14687308 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nutritional formula (8 oz/d) containing antioxidants, zinc, selenium, fermentable oligosaccharides, and structured triacylglycerol
Number of subjects: 66
Study 14687308 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic, isonitrogenous control formula
Number of subjects: 66
Study 14687308 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nutritional formula
Number of subjects: 66
Study 14687308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 11058714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day, n=24)
Number of subjects: 50
Study 11058714 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, n=26)
Number of subjects: 50
Study 11058714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 50
Study 9348449 — intervention group
Group type: EXPERIMENTAL
Intervention: Omafilcon A
Number of subjects: 30
Study 9348449 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A
Number of subjects: 30
Study 9348449 — intervention group
Group type: COMPARATOR
Intervention: Welcon CE
Number of subjects: 30
Study 8406153 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Vivonex TEN 2.1 l/day for four weeks)
Number of subjects: 42
Study 8406153 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (0.75 mg/kg/day for two weeks and subsequent reducing doses)
Number of subjects: 42
Study 8406153 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 42
Study 8406153 — intervention group
Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 42
Study 2426997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 446
Study 2426997 — intervention group
Group type: COMPARATOR
Intervention: No Lidocaine (Control)
Number of subjects: 446
Study 30661561 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP) for OCD
Number of subjects: 90
Study 28915080 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg reslizumab IV Q4W
Number of subjects: 10
Study 26631986 — intervention group
Group type: EXPERIMENTAL
Intervention: 'PREPARED ON TIME' e-learning program
Number of subjects: 254
Study 26631986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 254
Study 25193670 — intervention group
Group type: EXPERIMENTAL
Intervention: IRA occlusion in patients without diabetes
Number of subjects: 3046
Study 25193670 — intervention group
Group type: EXPERIMENTAL
Intervention: IRA occlusion in patients with diabetes
Number of subjects: 3046
Study 25193670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IRA occlusion in nondiabetic patients
Number of subjects: 3046
Study 25193670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IRA occlusion in diabetic patients
Number of subjects: 3046
Study 22395798 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine (any)
Number of subjects: 31370
Study 22395798 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 31370
Study 22395798 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura
Number of subjects: 31370
Study 22395798 — intervention group
Group type: EXPERIMENTAL
Intervention: New reports of migraine during follow‐up
Number of subjects: 31370
Study 22395798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior migraine
Number of subjects: 31370
Study 19447770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) - two cycles at baseline and 24 weeks, each cycle consisting of four weekly infusions (375 mg/m²)
Number of subjects: 14
Study 19447770 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (Control)
Number of subjects: 14
Study 17851890 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with carboplatin and uracil‐f tegafur (UFT)
Number of subjects: 62
Study 15283063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvisual walking
Number of subjects: 0
Study 11152857 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 88
Study 11152857 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 88
Study 9506636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 96
Study 9506636 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV)
Number of subjects: 96
Study 9506636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas exchange and ventilator support
Number of subjects: 96
Study 9506636 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraalveolar air
Number of subjects: 96
Study 9506636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial bleeding
Number of subjects: 96
Study 7827642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate + estradiol valerate
Number of subjects: 67
Study 7827642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate + transdermal estradiol
Number of subjects: 67
Study 2907735 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of glafenine twice a day
Number of subjects: 166
Study 2907735 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg of paracetamol twice a day
Number of subjects: 166
Study 4880261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramisole
Number of subjects: 200
Study 4880261 — intervention group
Group type: COMPARATOR
Intervention: Piperazine
Number of subjects: 200
Study 31112605 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based intervention (daily 30-min face-to-face semi-structured conversations with trained interviewers for 6 weeks)
Number of subjects: 83
Study 31112605 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based intervention
Number of subjects: 83
Study 31112605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 29668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-intensity laser therapy three times per week for 8 weeks, along with usual hormonal treatment
Number of subjects: 40
Study 29668354 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment three times per week for 8 weeks, along with usual hormonal treatment
Number of subjects: 40
Study 27924462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mujer Segura intervention
Number of subjects: 528
Study 26362692 — intervention group
Group type: EXPERIMENTAL
Intervention: AS cognitive concerns intervention
Number of subjects: 54
Study 26362692 — intervention group
Group type: COMPARATOR
Intervention: Health information control intervention
Number of subjects: 54
Study 23126316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser GaAlAs, energy density of 4 J/cm(2), power of 100 mW, wavelength in the infrared spectrum, for 10 seconds per point on 10 points, total dose of 40 J/cm(2)
Number of subjects: 60
Study 23126316 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (simulated laser application for 60 seconds per point on 10 points)
Number of subjects: 60